Target and Its Patented Drug(s)
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T67619 | Target Info | |||
| Target Name | RAC-alpha serine/threonine-protein kinase (AKT1) | ||||
| Synonyms | RAC-PK-alpha; RAC; Proto-oncogene c-Akt; Protein kinase B alpha; PKB alpha | ||||
| Target Type | Successful Target | ||||
| Gene Name | AKT1 | ||||
| Biochemical Class | Kinase | ||||
| UniProt ID | |||||
| Patent(s) and the Corresponding Patented Drug(s) | Top | ||||
|---|---|---|---|---|---|
| United States Patent and Trademark Office (USPTO) | |||||
| Patent ID | US2015374692 | ||||
| Title | Methods and Compositions Relating To The Treatment of Cancer. | ||||
| Representative Drug(s) | D07QBF | Drug Info | N.A. | [1] | |
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.